Veljače 2023 .: According to data published in JAMA Oncology, the global economic cost of cancer is projected to reach $25,2 trillion in international dollars (INT) between 2020 and 2050.
Predviđa se da će Sjeverna Amerika imati najveći trošak, a Kina da će imati najveći trošak po glavi stanovnika. Predviđa se da će rak dušnika, bronha i pluća izazvati najveće troškove.
Researchers used a macroeconomic model to make these forecasts. Between 2020 and 2050, they projected the cost of 29 cancers in 204 countries and territories.
The United States ($5,300 billion), China ($6,100 billion), and India ($1,400 billion) will bear the largest economic costs.
Bulgaria (1.42%), Monaco (1.33%), and Montenegro (1.0%) are the countries with the highest projected economic costs as a percentage of gross domestic product. The projected economic cost per capita is greatest in Monaco ($85,230), Ireland ($54,009), and Bermuda ($20,732)
North America is projected to have the highest economic burden from cancer as a proportion of gross domestic product, equivalent to a 0.83 percent annual tax. Europe and Central Asia (0.63%), East Asia and the Pacific (0.59%), and Sub-Saharan Africa (0.24%) follow.
Prema vrsti raka, najveći ekonomski trošak predviđa se za:
- Rak dušnika, bronha i pluća (INT 3.9 bilijuna dolara)
- Rak debelog crijeva i rektuma (INT 2.8 bilijuna dolara)
- Rak dojke (2.0 bilijuna dolara)
- Rak jetre (INT 1.7 bilijuna dolara)
- Leukemija (INT 1.6 bilijuna dolara)
Istraživači su primijetili da ti oblici raka čine polovicu globalne ekonomske cijene raka.
The researchers wrote, “The macroeconomic cost of cancer was found to be substantial and heterogeneously distributed across cancer types, countries, and world regions.” The findings indicate that global efforts to reduce the prevalence of cancer are warranted.
Povezani uvodnik istaknuo je ograničenja studije, uključujući nepostojanje podataka za 60 zemalja, ili 7.3% ukupne populacije.
Objave: Autori studije izvijestili su da nemaju sukoba interesa. Autor uvodnika izjavio je da je povezan s biotehnološkim, farmaceutskim tvrtkama i/ili tvrtkama za uređaje. Pogledajte izvorne reference za potpuni popis objava.
